Get the Stockscreener App
0.8998
3.25%
-0.0302
After Hours:
.95
0.0502
+5.58%
Clearside Biomedical Inc stock is traded at $0.8998, with a volume of 117.82K.
It is down -3.25% in the last 24 hours and up +13.54% over the past month.
See More
Previous Close:
$0.93
Open:
$0.9
24h Volume:
117.82K
Relative Volume:
0.59
Market Cap:
$69.41M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-1.6977
EPS:
-0.53
Net Cash Flow:
$-19.91M
1W Performance:
-12.64%
1M Performance:
+13.54%
6M Performance:
-32.35%
1Y Performance:
-37.08%
1-Day Range:
$0.8857
$0.94
1-Week Range:
$0.8857
$1.03
52-Week Range:
$0.7737
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Compare CLSD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.8998 | 69.41M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-24 | Initiated | Chardan Capital Markets | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan
Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World
HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire
Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks
Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks
Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan
Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Buys $13,800.00 in Stock - MarketBeat
Clearside Biomedical director Thorp Clay buys $13,800 in stock By Investing.com - Investing.com South Africa
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):